Drug Profile
Research programme: LFA-1 inhibitors - Actinobac Biomed
Alternative Names: Leukocyte function antigen-1 (LFA-1) antagonist - Actinobac Biomed; LeukotheraLatest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator University of Medicine & Dentistry of New Jersey
- Developer Actinobac Biomed
- Class Biological toxins
- Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Haematological malignancies; HIV infections; Psoriasis
Most Recent Events
- 22 Aug 2023 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 22 Aug 2023 Discontinued - Preclinical for Haematological malignancies in USA (unspecified route)
- 22 Aug 2023 Discontinued - Preclinical for HIV infections in USA (unspecified route)